New Clinical Trial: Combination Immunotherapy in Rare Cancers Under InvesTigation (NCT04969887)
WHY IT MATTERS
Patients with these rare cancers now have access to a targeted immunotherapy combination that showed promise in earlier studies, potentially offering a new treatment option for cancers that historically have limited therapeutic choices.
Researchers are testing a combination of two immunotherapy drugs in patients with four types of rare cancers: neuroendocrine tumors, biliary tract cancers, ovarian clear cell carcinoma, and tumors with high microsatellite instability. This Phase 2 trial involves 240 patients and is based on earlier research showing these cancers may respond well to this type of treatment.
NCT ID: NCT04969887 Status: ACTIVE_NOT_RECRUITING Conditions: Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor Phase: PHASE2 Enrollment: 240 Sponsor: Olivia Newton-John Cancer Research Institute Summary: The four tumour streams that will be studied in this protocol are based on immunotherapy sensitive rare cancers from CA209-538 which will be further investigated under this protocol and divided into four groups: 1. Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded) 2. Biliary tract cancers: Intrahepatic cholangiocarcinoma and gallbladder carcinoma 3. Gynaecological malignancies: Ovarian clear cell carcinoma
ASK YOUR DOCTOR
If you have one of these rare cancers, ask your oncologist whether you might be eligible for this trial or if the results from this research could apply to your treatment plan.